John Ragard
Fortuna: 37 591 $ al 31/08/2026
Fortuna: 37 591 $ al 31/08/2026
John Ragard formerly worked at Aspira Women's Health, Inc., as Director from 2024 to 2025 and Friess Associates LLC, as Research Team Leader from 1993 to 2014.
Mr. Ragard received his undergraduate degree from The Wharton School of the University of Pennsylvania.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 04/06/2025 | 134.734 ( 0,29 % ) | 37 591 $ | 31/08/2026 |
| Empresas | Cargo | Fin |
|---|---|---|
| ASPIRA WOMEN'S HEALTH INC. | Director/Miembro de la Junta | 04/06/2025 |
Friess Associates LLC
Friess Associates LLC Investment ManagersFinance Friess Associates is a discretionary investment manager that specializes in domestic (US) growth equity strategies. The firm offers growth equity strategies across the market capitalization spectrum ranging from micro to large. Accordingly, clients may choose a focused market capitalization strategy within that range or an all-capitalization strategy. They employ a research-driven investment process, and primarily utilize fundamental analysis for the selection of equity investments. Friess Associates will sell a stock when its research determines: (1) a company has deteriorating fundamentals such as contracting margins or reduced revenue growth, (2) investor expectations have become unrealistically high, (3) when it reaches Friess Associates’ internal target price, and (4) identifies a better investment idea. | Gestor de Cartera-Acciones | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 3 |
|---|---|
Friess Associates LLC
Friess Associates LLC Investment ManagersFinance Friess Associates is a discretionary investment manager that specializes in domestic (US) growth equity strategies. The firm offers growth equity strategies across the market capitalization spectrum ranging from micro to large. Accordingly, clients may choose a focused market capitalization strategy within that range or an all-capitalization strategy. They employ a research-driven investment process, and primarily utilize fundamental analysis for the selection of equity investments. Friess Associates will sell a stock when its research determines: (1) a company has deteriorating fundamentals such as contracting margins or reduced revenue growth, (2) investor expectations have become unrealistically high, (3) when it reaches Friess Associates’ internal target price, and (4) identifies a better investment idea. | Finance |
Aspira Women's Health, Inc.
Aspira Women's Health, Inc. BiotechnologyHealth Technology Develops and manufactures diagnostic test kits | Health Technology |
The Wharton School of the University of Pennsylvania
The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.